

A Research Article On: Intersecting Epidemics of Many Unknowns: HIV & Covid-19

¹Prince Kumar, ²Gangaram Bhadarge, ³Shubhada Gade, ⁴Abhishek Joshi

¹First Year Mbbs Student, Datta Meghe Medical College, Nagpur.

²Tutor Dept. Of Biochemistry Jawaharlal Nehru Medical College, Datta Meghe Institute Of Medical Sciences Sawangi (Meghe) Wardha

³Professor And Hod Dept. Of Physiology Datta Meghe Medical College, Shalinitai Meghe Hospital And Research Centre Nagpur

⁴Associate Professor Dept. Of Community Medicine Jawaharlal Nehru Medical College, Datta Meghe Institute Of Medical Sciences Sawangi (Meghe) Wardha

Abstract

since of July 2020, about 6 months keen on the epidemic of new corona virus illness 2019, the question of why persons infected with human immunodeficiency virus (HIV; PLWH) are negatively impacted remained unanswered (COVID-19). So far, COVID-19 vulnerability appears to be equivalent in persons with and without HIV, however findings may be contradictory. Some of the misunderstanding arises from COVID-19's newness and shortage of data; others stem from ambiguity regarding come again? it resources for HIV to be a "risk factor" for COVID-19.

INTRODUCTION

Covid-19 has a diameter of 65 nm to 125 nm and has single-stranded RNA as their nucleus. Transmission of Covid-19 on a worldwide scale, its recurrence, and the huge number of deaths Physical contact was the most common way for the virus to spread from person to person. Droplets are formed by coughing, sneezing, and laughing. COVID-19 infection is characterized by fever, chills, cough, sore throat, difficulty breathing, myalgia or tiredness, nausea, vomiting, and diarrhea. Wuhan, the funds of Hubei region and residence to 11 million people, was the first place where the novel coronavirus be discovered. The COVID-19 virus quickly expanded to other nations in January 2019, including Thailand, Japan, Korea, the United States, and Iran. Chinese scientists identified the etiological culprit of the outbreak as 2019-nCoV, a previously unknown coronavirus, on 7 th January 2020, (for 2019 novel corona virus). By viral classification, the novel coronavirus illness is selected corona virus infection 19 (COVID-19) through the (WHO) on February 11, 2020. Fever, cough, and tiredness are the mainly general symptoms of COVID-19, as are myalgia, sputum production, and headache. Because December 2019, an unusual pneumonia (corona virus illness 2019 (COVID-19) have be spreading across China from Wuhan, a lovely capital in the heart of the nation. It's unclear if PLWH are more likely to develop SARS-CoV-2 or have worse health outcomes following infection. There are several grounds to assume that PLWH are in grave danger: PLWH have weakened immune responses to immune system challenges, and they have a high incidence of danger factor for severe covid-19 illness, such as blood pressure, dm, cvd, obese, lung disease, smoke, male sex, and advanced age.^{1,2}

Poorer COVID-19 outcome, on the other hand, strength be related to untouchable (over) creation, and therefore PLWH may be at a reduced risk of worse outcome following SARS-CoV-2 disease due to their weaker immune system. yet, there isn't currently enough statistics to maintain or disprove any of these hypothesis. Data is scarce early in the course of a new disease epidemic, and the case report or case series (4–8) is the most realistic, if not the only, epidemiologic study method available. Attempts to assess the commonness of previous SARS-CoV-2 virus in PLWH, like attempts to estimate incidence, must consider who is and is not integrated in several sero examination. Residents in a few states are being erratically sampled for sero inspection (19); these serosurveys might give estimate of previous SARS-CoV-2 contamination in PLWH if sampling procedures take specific interest groups, such as PLWH, into account. A "RISK FACTOR" FOR HEPATITIS C.^{3,4}

Researchers must carefully analyse the study problem at hand as well as how the findings will be used in order to perform effective epidemiologic research on the property of COVID-19 on PLWH. It's fair to be concerned about HIV being labelled as a "independent risk factor" for deprived COVID-19 findings base happening an artificial multivariable model, since this might lead to inappropriate care rationing or treatment decisions. Demographic and scientific uniqueness of in Wuhan's Wuchang and Qinshan districts had COVID-19 (0.7 percent as of the end of February or start of March 2020), which was similar to the common residents threat (0.5 percent) (14). COVID-19 had been identified in 51 (3.8 percent) of 1,339 PLWH under daily therapy in Madrid, Spain as of April 30, 2020. The COVID-19 risk in Madrid (4.0 percent) was comparable for the same time period. Finally, the SARS-CoV-2 positive percentage among PLWH examined in a Chicago, Illinois medical centre (15%) was comparable to the HIV-negative people's positivity rate (19 %). (16).⁶

Unpublished observation records from South Africa's Western Cape region show that PLWH are 2.3 times more likely to die from COVID-19 than those lacking HIV, despite both cohorts indicating identical disease obligation in citizens through and exclusive of HIV.⁷ In terms of what they're looking for, the current research on the link between HIV and COVID-19 findings hasn't always been consistent. The findings were consistent in a retrospective matched cohort of PLWH and individuals without HIV hospitalised in New York for COVID-19. HIV disease indicators such as HIV viral load and CD4 cell count, which would be predictable to be the strongest peacekeepers of a straight influence of HIV infectivity on COVID-19 outcome, have not been found to be closely linked with COVID-19 morbidity between PLWH. These findings should be interpreted with caution because only SARS-CoV-2 infection that resulted in indicative disease have been studied thus far; HIV may influence whether SARS-CoV-2 infections are observed, either because PLWH have extra or a smaller amount contact to transmission or since HIV may raise the fraction of infection that are indicative. The significant frequency of HIV viral suppression in COVID-19 cases implies that PLWH who do not have access to HIV therapy be with a reduction of liable to be diagnosed with COVID-19 or to be recorded as HIV-infected in the findings.⁸

AIM

A RESEARCH ARTICLE ON: INTERSECTING EPIDEMICSO F MANY UNKNOWN S: HIV & COVID-19

MATERIAL AND METHOD

The material required for the review was taken from the databases of PubMed , Web of science ,the from the website of World Health Organization and the patients data of SMHRC and DMMC Wanadongari Nagpur

DISCUSSION

THE Effect OF ANTIRETROVIRAL MEDICATIONS ON THE PROGRESSION OF COVID-19 virus

Some antiretroviral drugs, such as lopinavir-ritonavir (a protease inhibitor), have been suggested and tested as treatment for other coronaviruses with similar symptoms. Though, a study of 199 patients randomised to lopinavirritonavir vs. ordinary of mind establish simply minor difference in time to scientific development (hazard ratio = 1.24, 95 percent self-belief intermission: 0.90, 1.72) and 28-day death (risk difference = 5.8%, 95 percent confidence interval: 17.3 percent, 5.7 percent). While the findings were inconclusive, there was some evidence that the effect of lopinavir-ritonavir on transience was higher if care was started sooner after the onset of symptoms. The findings indicated that lopinavir-ritonavir had “no benefit,” but there were some correlations that suggested a possible protective effect. Although these findings do not favour starting lopinavir-ritonavir care in SARS-CoV-2 patients, they may mean. The amount of data on the relationship between ART regimen and COVID-19 outcome is also insufficient to endorse or rule out any specific regimen.⁹⁻¹¹

MODIFYING, MEASUREMENT, AND MONITORING CARE ENGAGEMENT

PLWH's welfare depends on their willingness to participate in continuing treatment. Every 3–6 months, HIV viral load and CD4 cell tally must be tested. Due to the danger of SARS-CoV-2 transmission associated with face-to-face interaction, especially in health check setting, several experimental contacts (for all persons, together with PLWH) were quickly converted. There is currently no evidence on the short- and long-term effects of telehealth on PLWH's interest in treatment and adherence to ART. >90% of patients in a Missouri HIV centre, according to a narrative survey (presumably among those who successfully performed a telehealth appointment) indicated that their telehealth visit was as good as or better than a typical in-clinic visit during COVID-19 physical distancing constraints.^{12,13}

The number of patients who did not complete a telehealth appointment was not given. Just 21% of planned appointments were completed practically at a Chicago clinic from late March to mid-April. Rescheduled events accounted for 31%, in-person events accounted for 2%, and 46 percent were not attended.¹⁴ Lack of appropriate technologies and resources, as well as a lack of technology awareness and a safe, private environment in which to participate completely in telehealth, can be obstacles to full participation in treatment . There is a lack of healthy, representative data on smartphone ownership and internet usage among the PLWH.¹⁵ In the Bronx in 2014, 87 percent of a group of mainly low-income women of colour pursuing HIV-related social or clinical care possessed a smartphone, compared to 90 percent–92 percent of the general population at the time. Just 60% of PLWH in British Columbia, Canada, who were recruited in 2012 had a cellphone at the time of registration. In the general population of the United States, demographic patterns associated with

inadequate access to smartphones and home internet networks match the demographics of those with a high incidence of HIV infection: non-White individuals, older adults, and those with reduced schooling or lower income. Furthermore, merely possessing a mobile phone is insufficient for telehealth to be reliable. Patients that do not have unrestricted phone or internet coverage can incur extra monetary expenses for telehealth visits. Furthermore, PLWH may have safety issues when receiving medical attention outside of the facility, where they may not be in charge of their surroundings. In a study of PLWH's perceptions about telehealth in general, nearly a quarter expressed doubt over their capacity to communicate themselves without a face-to-face contact. Potential telehealth costs, advantages, and priorities are likely to differ among PLWH, and this variability will need to be taken into account when guiding clinical practise (e.g., prioritising patients for in-clinic visits versus continued telehealth visits when clinics reopen).but with a low patient population in the clinic to allow for physical separation). Those considerations that are likely to change the impact of telehealth on patient interaction (access to the internet and a secure, protected place from which to dial in, as well as distance and transportation to the clinic) should be obtained on a regular basis. Another reason that is sure to disrupt treatment in the United States is the global downturn triggered by the pandemic, which resulted in millions of people losing their employment and employer-sponsored benefits. If PLWH who previously had private insurance unexpectedly lose their ability to pay for coverage, they will face delays in care. Clinical cohorts provide a rare way to monitor improvements in insurance status and how they affect patient involvement, ART access, and viral suppression. This will necessitate further follow-up with lost-to-clinic patients to assess why they have not returned.¹⁶⁻¹⁸

COMORBIDITIES BETWEEN SUBSTANCE USE AND MENTAL HEALTH

Alcoholism, other substance abuse, and mental health issues are all frequent in PLWH, and they may offer unique dangers and challenges during the SARS-CoV-2 pandemic. Prohibitions on physical separation, as well as the despair and anxiety that accompany them, can lead to an increase in the use of alcohol and other substances. Epidemiologists should seek for new data sources to map any of these occurrences. Nielsen Retail Measurement Services, for example, reports a considerable increase (+234%) in internet wine purchases and sales of larger amounts of alcohol (40). To move beyond ecological inference, we'll need to focus on more conventional polls of alcohol and other drug usage to figure out if individual PLWH are increasing their use and changing when and how they use alcohol and other drugs.¹⁹⁻²⁰

Physical distance restrictions are likely to aggravate pre-existing mental health issues. Individuals have historically relied on artistic outlets to help them cope. Physical distance constraints can demolish social structures and creative outlets that have previously helped persons cope. PLWH, particularly senior PLWH, are already at high risk of social isolation. Breaking the physical separation principle in order to locate these coping strategies may result in increased stress as a result of SARS-CoV-2 exposure or stigma. Accurate risk assessments for PLWH are required to assist participants in weighing the hazards and advantages of participation in such activities, but they are currently unavailable. People who can protection in position in their home may face more stress if they are alone in their houses, if staying at home imposes supplementary care generous duties, or if they live with an important person who offers a physical or touching risk.²¹⁻²²

While mental health treatment may be one of the care facilities most suited to cassette conferencing, it may also act as a "canary in the coal mine" for growing inequities in access to technology and personal, secure spaces for therapy. For model, one HIV clinic in Chicago, Illinois, discovered that several patients who had been getting rational strength therapy previous to the implementation of bodily hostility interventions provisionally stopped receiving it when it was delivered via telehealth, while others began receiving it for the first time. People through strict rational wellbeing symptom may be extra vulnerable to SARS-CoV-2 infection if their understanding of public health messaging is impaired or if they do not appreciate their opportunity and how to moderate it, in accumulation to having their psychological potency symptoms exacerbate as a effect of substantial separation.²³⁻²⁴

CONCLUSION

The COVID-19 pandemic would have ramifications on everyone's health and well-being. Citizens breathing with HIV/AIDS are extra possible to be affected directly and indirectly by the epidemic. Is it feasible to pay closer attention to PLWH for COVID-19? Are there any PLWH testing questions that have yet to be answered in the United States? Is HIV status linked to an enlarged threat of SARS-CoV-2 illness or worse COVID-19 outcomes in persons infected with SARS-CoV-2? A comprehensive HIV testing infrastructure offers many options for addressing some of these persisting concerns. What are the effects of physical separation therapies on PLWH, specifically on HIV treatment, drug use, and mental health outcomes, as well as other systemic factors impacting health outcomes? Since stretched as we hold to high epidemiologic standards in terms of addressing well-defined issues, a strong HIV testing infrastructure offers several opportunities to address some of these lingering concerns. To take advantage of these opportunities to impact public health practise, the core study topic must be correctly specified, and appropriate analyses must be used to answer the question.

REFERENCES

1. Bhadarge, Gangaram L, Nandkishor Bankar, Saurabh Hadke, Study of Liver Function Test, Haematological Parameters Crp Derangements in Covid-19 Patients. Special Issue Vol 14 No 06 (2021) Pp-36-40.
2. Mascolo S, Romanelli A, Carleo MA, et al. Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better. [Published online ahead of print April 15, 2020]. *J Med Virol*.
3. Zhu F, Cao Y, Xu S, et al. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. *J Med Virol*. 2020;92(6):529–530.
4. Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. *Lancet HIV*. 2020;7(5):e314–e316.
5. Joob B, Wiwanitkit V. SARS-CoV-2 and HIV. [Published online ahead of print March 27, 2020]. *J Med Virol*.
6. Altuntas Aydin O, Kumbasar Karaosmanoglu H, Kart Yasar K. HIV/SARS-CoV-2 co-infected patients in Istanbul, Turkey. [Published online ahead of print April 29, 2020]. *J Med Virol*.
7. Sun LJ, Wong SXL, Gollamudi S. A case of HIV and SARS-CoV-2 co-infection in Singapore. *J Acquir Immune Defic Syndr*. 2020;84(4):e23–e24.
8. Baluku JB, Mwebaza S, Ingabire G, et al. HIV and SARS-CoV-2 co-infection: a case report from Uganda. [Published online ahead of print May 21, 2020]. *J Med Virol*.

9. Zhao J, Liao X, Wang H, et al. Early virus clearance and delayed antibody response in a case of coronavirus disease 2019 (COVID-19) with a history of coinfection with human immunodeficiency virus type 1 and hepatitis C virus. [Published online ahead of print April 9, 2020]. *Clin Infect Dis*.
10. Gervasoni C, Meraviglia P, Riva A, et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. [Published online ahead of print May 14, 2020]. *Clin Infect Dis*.
11. Haerter G, Spinner CD, Roeder J, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. *Infection*. 2020;48:681–686.
12. Baluku JB, Olum R, Agolor C, et al. Prevalence, clinical characteristics and treatment outcomes of HIV and SARS-CoV-2 co-infection: a systematic review and meta-analysis. *medRxiv*. 2020.
13. Guo W, Ming F, Dong Y, et al. A survey for COVID-19 among HIV/AIDS patients in two districts of Wuhan, China. *SSRN*. 2020.
14. Vizcarra P, Pérez-Elías MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-Centre, prospective cohort. *Lancet HIV*. 2020;7(8):E554–E564.
15. Ridgway JP, Schmitt J, Friedman E, et al. HIV care continuum and COVID-19 outcomes among people living with HIV during the COVID-19 pandemic, Chicago, IL. *AIDS Behav*. 2020;24(10):2770–2772.
16. Alcorn K. People with HIV at greater risk of COVID-19 death in South African study. <https://www.aidsmap.com/news/jun-2020/people-hiv-greater-risk-covid-19-death-south-african-study>. Accessed June 29, 2020.
17. 34. Dr. Swati Maldhure, Dr. Ranjit Ambad, Dr. Sanika Kalambe. COVID-19 AND OTORHINOLOGOLOGY: PREVENTION BETTER THAN CURE. *Journal of critical reviews*. Vol 7, Issue 10, 2020; 122-125.
18. Nunes R. Blood tests show 2.2 percent of Rliers have coronavirus antibodies. *Patch*. 2020. <https://patch.com/rhode-island/cranston/blood-tests-show-2-2-percent-riers-have-coronavirus-antibodies>. Accessed June 29, 2020.
19. Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *MedRxiv*. 2020. Accessed September 29, 2020.
20. Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. *Am J Epidemiol*. 2013;177(4):292–298.
21. Kaufman JS. Statistics, adjusted statistics, and maladjusted statistics. *Am J Law Med*. 2017;43(2–3):193–208.
22. Savannah K-T, Philip MC, Fainareti NZ, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. *J Acquir Immune Defic Syndr*. 2020;85(1):6–10.
23. Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and people living with human immunodeficiency virus: outcomes for hospitalized patients in New York City. [Published online ahead of print June 28, 2020]. *Clin Infect Dis*.
24. Zumla A, Chan JFW, Azhar EI, et al. Coronaviruses—drug discovery and therapeutic options. *Nat Rev Drug Discov*. 2016;15(5):327–347.
25. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. *N Engl J Med*. 2020;382(19):1787–1799.